Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GSK and Impax Terminate Their Collaboration

Published: Tuesday, April 30, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
The companies are terminating their collaboration for the development and commercialisation of IPX066 outside the United States and Taiwan.

IPX066 is a carbidopa-levodopa extended release product in Phase III development for the symptomatic treatment of Parkinson’s disease and is not approved anywhere in the world.

Under the terms of the agreement entered into in December 2010, GSK’s right to develop and commercialise IPX066 outside the United States and Taiwan will transfer back to Impax with effect at the end of July 2013.  The decision has been reached because of delays in the anticipated regulatory approval and launch dates in countries in which GSK has rights to commercialise the product. Impax will take over development of IPX066 on a worldwide basis while seeking the opportunity to partner its rights in markets outside of the United States.

GSK remains committed to discovering, developing and delivering innovative medicines for patients with Parkinson’s disease.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GSK Awarded Up to $200 Million by U.S. Government to Develop New Antibiotics
Funding will support development of drugs to fight antibiotic resistance and bioterrorism.
Friday, May 24, 2013
GSK and Impax Pharmaceuticals Terminate Their Collaboration on IPX066
Both Companies end collaboration for the development and commercialization of IPX066 outside the United States and Taiwan.
Tuesday, May 07, 2013
GSK and GlaxoSmithKline Consumer Nigeria PLC Announces Agreement
GSK to increase its stake in GlaxoSmithKline Consumer Nigeria PLC.
Friday, November 30, 2012
GSK to Fully Acquire Cellzome for £61 Million
GSK to further expand its platform technology expertise with acquisition of chemical proteomics company.
Wednesday, May 16, 2012
GSK and University of Nottingham Collaborate to Create Centre of Excellence for Sustainable Chemistry
Innovative carbon neutral laboratory to be established on University Campus.
Friday, April 27, 2012
GlaxoSmithKline in Pioneering Collaboration with The University of Nottingham
A new facility focused on the development of ‘green chemistry’ technology is part of a pioneering new partnership.
Wednesday, December 01, 2010
APPLES Consortium to Develop Improved In-Line Liquid Monitoring Technologies to Manufacture High-Value Products
New sensor system to be based on Stratophase’s SpectroSens optical microchip technology.
Wednesday, March 31, 2010
GlaxoSmithKline Update: Government Orders for Pandemic (H1N1) 2009 Vaccine
GSK is supporting governments and health authorities around the world respond to the pandemic (H1N1) 2009 influenza strain.
Monday, August 10, 2009
GSK Extends Strategic Collaboration with Aspen
GSK to acquire 16% shareholding in Aspen in exchange for transfer of specialist products and manufacturing facility in Bad Oldesloe, Germany.
Thursday, May 14, 2009
GlaxoSmithKline and Pfizer Announce Agreement to Create a Specialist HIV Company
Creates a new focused HIV business with the independence and sustainability to deliver improvements in treatment, access and shareholder value.
Friday, April 17, 2009
GlaxoSmithKline to Acquire Genelabs to Increase Focus on Small Molecule Therapies for Hepatitis C
Under the terms of the agreement, a subsidiary of GSK will commence a tender offer to acquire all of the outstanding shares of Genelabs common stock.
Thursday, October 30, 2008
GlaxoSmithKline and Tolerx Form Worldwide Collaboration for Development and Commercialization of Novel Medication
Collaboration aims to develop and commercialize a humanized anti-CD3 monoclonal antibody against type 1 diabetes and other autoimmune indications.
Wednesday, October 24, 2007
GlaxoSmithKline and Synta Announce Development and Commercialization Collaboration
The global collaboration agreement aim to develop and commercialize STA-4783 for the treatment of metastatic melanoma.
Thursday, October 11, 2007
GlaxoSmithKline Research Chooses Spotfire
Spotfire DecisionSite has been chosen by the IT team within GSK's Chemistry Domain.
Monday, October 02, 2006
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!